BioCryst Pharmaceuticals Inc (BCRX) Financials
Key financial figures for BioCryst Pharmaceuticals Inc (Q3 2026).
BioCryst Pharmaceuticals, Inc. reported revenue of $180.3 million for Q3 FY2026, up 13.1% from the same period a year earlier. Net income was $37.9 million, or $0.14 per share. Operating margin came to 29.58%, against 18.56% a year earlier. Free cash flow for the period was $32.8 million. Across the last 5 reported quarters, quarterly revenue has risen from $159.4 million in Q3 FY2025 to $180.3 million in Q3 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for BioCryst Pharmaceuticals, Inc. are on the SentiSense financials page.
- Revenue
- $180M
- Net Income
- $38M
- EPS
- $0.15
- Total Assets
- $591M
- Operating Cash Flow
- $33M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $180M | $38M | $0.14 | 29.58% | $33M |
| Q2 FY2026 | $218M | $78M | $0.30 | 45.12% | $104M |
| Q1 FY2026 | $156M | -$722M | -$2.98 | -448.55% | -$63M |
| Q4 FY2025 | $407M | $246M | $1.12 | 64.05% | $275M |
| Q3 FY2025 | $159M | $13M | $0.06 | 18.56% | $40M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $875M | $264M | $1.21 | 38.98% | $327M |
| FY2024 | $451M | -$89M | -$0.43 | -0.56% | -$53M |
| FY2023 | $331M | -$227M | -$1.18 | -31.29% | -$97M |
Frequently asked questions
What was BioCryst Pharmaceuticals, Inc.'s revenue last quarter?
BioCryst Pharmaceuticals, Inc. reported revenue of $180.3 million for Q3 FY2026, up 13.1% from the same period a year earlier.
Is BioCryst Pharmaceuticals, Inc. profitable?
Yes. BioCryst Pharmaceuticals, Inc. reported net income of $37.9 million for Q3 FY2026, a net margin of 21.03% on revenue.
How has BioCryst Pharmaceuticals, Inc.'s margin trended?
Operating margin was 29.58% in Q3 FY2026, compared with 18.56% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did BioCryst Pharmaceuticals, Inc. generate?
BioCryst Pharmaceuticals, Inc. generated free cash flow of $32.8 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for BioCryst Pharmaceuticals Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.